Glial Fibrillary Acidic Protein: A Potential Therapeutic Target for Migraine
Department of Neurology, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, China
| Abstract: | Glial fibrillary acidic protein (GFAP), a pivotal intermediate filament protein predominantly expressed in astrocytes, serves as a core structural and functional regulator in the central nervous system, and is deeply implicated in the pathological cascades underlying a wide spectrum of neurological disorders, ranging from neurodegenerative diseases to neuroinflammatory conditions and episodic neurological disorders. In this paper, we reviewed the current research progress on the biological function, expression regulation and involvement in the process of neuroinflammation of GFAP, and discussed the potential of GFAP as a new target for the treatment of migraine. We reviewed the epidemiological characteristics, complex pathophysiological mechanisms, and clinical burden of migraine, a highly prevalent neurovascular disorder, while underscoring the inherent limitations of current mainstream therapeutic approaches, including incomplete efficacy, frequent recurrence, and prominent adverse effects, which highlight the unmet clinical demand for novel, targeted, and mechanism-driven therapeutic strategies. Evidence from preclinical and clinical studies suggests that the regulation of GFAP may affect the key mechanisms of migraine, including glial cell activation, neuroinflammation and neuronal excitability. Although challenges associated with technical barriers in drug development remain, this review highlights the translational potential of targeting GFAP to improve patient outcomes. Future interdisciplinary research and collaborative efforts are crucial for the introduction of GFAP based therapy into clinical practice. |
| Keywords: | GFAP; Glial Cells; Migraine; Neuroinflammation; Therapeutic Target |
| DOI: | 10.57237/j.wjcm.2026.01.001 |
View:
Downloads:
Received: 6 January 2026
Accepted: 3 February 2026
Published Online: 6 February 2026
References
| [1] | Eliasson C, Sahlgren C, Berthold CH, Stakeberg J, Celis JE, Betsholtz C, et al. Intermediate filament protein partnership in astrocytes. J Biol Chem. 1999; 274: 23996-24006. https://doi.org/10.1074/jbc.274.34.23996 |
| [2] | Eng LF, Ghirnikar RS, Lee YL. Glial fibrillary acidic protein: GFAP-thirty-one years (1969-2000). Neurochem Res. 2000; 25: 1439-1451. https://doi.org/10.1023/a:1007677003387 |
| [3] | Petrou P, Kassis I, Levi Y, Yaghmour N, Epstein T, Ginzberg A, et al. Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients treated with repeated administrations of autologous mesenchymal stem cells (MSC-NG01). J Neuroimmunol. 2025; 403: 578613. https://doi.org/10.1016/j.jneuroim.2025.578613 |
| [4] | Patel N, Agrawal N, Mishra R, Rekha MM, Nayak PP, Kaur M, et al. Emerging blood biomarkers in Alzheimer's disease: a proteomic perspective. Clin Chim Acta. 2025; 576: 120397. https://doi.org/10.1016/j.cca.2025.120397 |
| [5] | Bazarian JJ, Zetterberg H, Buki A, Dengler BA, Diaz-Arrastia R, Korley FK, et al. Blood-Based Biomarkers for Improved Characterization of Traumatic Brain Injury: Recommendations from the 2024 National Institute for Neurological Disorders and Stroke Traumatic Brain Injury Classification and Nomenclature Initiative Blood-Based Biomarkers Working Group. J Neurotrauma. 2025; 42: 1065-1085. https://doi.org/10.1089/neu.2024.0581 |
| [6] | Samadzadeh S, Sleator RD. The role of Neurofilament light (NfL) and glial fibrillary acidic protein (GFAP) in MS and AQP4-NMOSD: Advancing clinical applications. eNeurologicalSci. 2025; 38: 100550. https://doi.org/10.1016/j.ensci.2025.100550 |
| [7] | Kim KY, Shin KY, Chang KA. GFAP as a Potential Biomarker for Alzheimer's Disease: A Systematic Review and Meta-Analysis. Cells. 2023; 12: 1309. https://doi.org/10.3390/cells12091309 |
| [8] | Shan F, Long Y, Qiu W. Autoimmune Glial Fibrillary Acidic Protein Astrocytopathy: A Review of the Literature. Front Immunol. 2018; 9: 2802. https://doi.org/10.3389/fimmu.2018.02802 |
| [9] | Rushendran R, Vellapandian C. Advances in Migraine Treatment: A Comprehensive Clinical Review. Curr Protein Pept Sci. 2025; 26: 422-435. https://doi.org/10.2174/0113892037329429241123095325 |
| [10] | Gopalakrishnan R, Malan NS, Mandava N, Dunn EJ, Nero N, Burgess RC, et al. Magnetoencephalography studies in migraine and headache disorders: A systematic review. Headache. 2025; 65: 353-366. https://doi.org/10.1111/head.14867 |
| [11] | Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018; 17: 174-182. https://doi.org/10.1016/S1474-4422(17)30435-0 |
| [12] | Conti F, Pietrobon D. Astrocytic Glutamate Transporters and Migraine. Neurochem Res. 2023; 48: 1167-1179. https://doi.org/10.1007/s11064-022-03849-w |
| [13] | Cropper HC, Conway CM, Wyche W, Pradhan AA. Glial activation in pain and emotional processing regions in the nitroglycerin mouse model of chronic migraine. Headache. 2024; 64: 973-982. https://doi.org/10.1111/head.14740 |
| [14] | Baba H, Nakahira K, Morita N, Tanaka F, Akita H, Ikenaka K. GFAP gene expression during development of astrocyte. Dev Neurosci. 1997; 19: 49-57. https://doi.org/10.1159/000111185 |
| [15] | Viedma-Poyatos Á, González-Jiménez P, Pajares MA, Pérez-Sala D. Alexander disease GFAP R239C mutant shows increased susceptibility to lipoxidation and elicits mitochondrial dysfunction and oxidative stress. Redox Biol. 2022; 55: 102415. https://doi.org/10.1016/j.redox.2022.102415 |
| [16] | Crivellaro G, Tottene A, Vitale M, Melone M, Casari G, Conti F, et al. Specific activation of GluN1-N2B NMDA receptors underlies facilitation of cortical spreading depression in a genetic mouse model of migraine with reduced astrocytic glutamate clearance. Neurobiol Dis. 2021; 156: 105419. https://doi.org/10.1016/j.nbd.2021.105419 |
| [17] | Finch CE. Neurons, glia, and plasticity in normal brain aging. Neurobiol Aging. 2003; 24 Suppl 1: S123-127. https://doi.org/10.1016/s0197-4580(03)00051-4 |
| [18] | Pekny M, Wilhelmsson U, Bogestål YR, Pekna M. The role of astrocytes and complement system in neural plasticity. Int Rev Neurobiol. 2007; 82: 95-111. https://doi.org/10.1016/S0074-7742(07)82005-8 |
| [19] | Ur Rehman A, Ahmed A, Ali T, Ali M, Jamil N, Malik FA, et al. Evaluating the S100β, GFAP, IL-6, and Oxidative Stress Markers in Traumatic Brain Injury. Cureus. 2025; 17: e90329. https://doi.org/10.7759/cureus.90329 |
| [20] | Luo Y, Tu Q. Cerebrospinal fluid glial fibrillary acidic protein-antibody in idiopathic intracranial hypertension: a case report. Acta Neurol Belg. 2023; 123: 1557-1559. https://doi.org/10.1007/s13760-022-02024-w |
| [21] | Tomizawa Y, Okada H, Miyachi M, Hoshino Y, Cossu D, Kimura A, et al. Apathy in autoimmune GFAP Astrocytopathy: A case series and literature review. J Neuroimmunol. 2025; 408: 578733. https://doi.org/10.1016/j.jneuroim.2025.578733 |
| [22] | Brenner M. Structure and transcriptional regulation of the GFAP gene. Brain Pathol. 1994; 4: 245-257. https://doi.org/10.1111/j.1750-3639.1994.tb00840.x |
| [23] | Doecke JD, Bellomo G, Vermunt L, Alcolea D, Halbgebauer S, In 't Veld S, et al. Diagnostic performance of plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL along the continuum of Alzheimer's disease and non-AD dementias: An international multi-center study. Alzheimers Dement. 2025; 21: e14573. https://doi.org/10.1002/alz.14573 |
| [24] | Shir D, Graff-Radford J, Hofrenning EI, Lesnick TG, Przybelski SA, Lowe VJ, et al. Association of plasma glial fibrillary acidic protein (GFAP) with neuroimaging of Alzheimer's disease and vascular pathology. Alzheimers Dement (Amst). 2022; 14: e12291. https://doi.org/10.1002/dad2.12291 |
| [25] | Cousins KAQ, Irwin DJ, Chen-Plotkin A, Shaw LM, Arezoumandan S, Lee EB, et al. Plasma GFAP associates with secondary Alzheimer's pathology in Lewy body disease. Ann Clin Transl Neurol. 2023; 10: 802-813. https://doi.org/10.1002/acn3.51768 |
| [26] | Peretti DE, Boccalini C, Ribaldi F, Scheffler M, Marizzoni M, Ashton NJ, et al. Association of glial fibrillary acid protein, Alzheimer's disease pathology and cognitive decline. Brain. 2024; 147: 4094-4104. https://doi.org/10.1093/brain/awae211 |
| [27] | Abdelhak A, Huss A, Kassubek J, Tumani H, Otto M. Serum GFAP as a biomarker for disease severity in multiple sclerosis. Sci Rep. 2018; 8: 14798. https://doi.org/10.1038/s41598-018-33158-8 |
| [28] | Azzolini F, Gilio L, Pavone L, Iezzi E, Dolcetti E, Bruno A, et al. Neuroinflammation Is Associated with GFAP and sTREM2 Levels in Multiple Sclerosis. Biomolecules. 2022; 12: 222. https://doi.org/10.3390/biom12020222 |
| [29] | Maiworm M, Koerbel K, Anschütz V, Jakob J, Schaller-Paule MA, Schäfer JH, et al. BDNF levels in serum and CSF are associated with clinicoradiological characteristics of aggressive disease in MS patients. J Neurol. 2025; 272: 147. https://doi.org/10.1007/s00415-024-12875-3 |
| [30] | GBD 2021 Diseases and Injuries Collaborators. Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2024; 403: 2133-2161. https://doi.org/10.1016/S0140-6736(24)00757-8 |
| [31] | Burch R, Rizzoli P, Loder E. The Prevalence and Impact of Migraine and Severe Headache in the United States: Figures and Trends From Government Health Studies. Headache. 2018; 58: 496-505. https://doi.org/10.1111/head.13281 |
| [32] | Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018; 38: 1-211. https://doi.org/10.1177/0333102417738202 |
| [33] | Schulte LH, Peng KP. Current understanding of premonitory networks in migraine: A window to attack generation. Cephalalgia. 2019; 39: 1720-1727. https://doi.org/10.1177/0333102419883375 |
| [34] | Ebersberger A. Pathophysiology of migraine: models to explain the generation of migraine headache. Anaesthesist. 2002; 51: 661-667. https://doi.org/10.1007/s00101-002-0342-5 |
| [35] | de Vries T, Villalón CM, MaassenVanDenBrink A. Pharmacological treatment of migraine: CGRP and 5-HT beyond the triptans. Pharmacol Ther. 2020; 211: 107528. https://doi.org/10.1016/j.pharmthera.2020.107528 |
| [36] | Subalakshmi S, Rushendran R, Vellapandian C. Revisiting Migraine Pathophysiology: from Neurons To Immune Cells Through Lens of Immune Regulatory Pathways. J Neuroimmune Pharmacol. 2025; 20: 30. https://doi.org/10.1007/s11481-025-10197-3 |
| [37] | Fahmy EM, Nada MA, El Hamid NAA, Sharaf SAE, Osama W, Elshebawy H. Migraine and ergot use increase plasma pentraxin 3 levels: an Egyptian study. Neurol Res. 2025; 47: 155-162. https://doi.org/10.1080/01616412.2025.2456708 |
| [38] | Chiang CC, Schwedt TJ. Calcitonin gene-related peptide (CGRP)-targeted therapies as preventive and acute treatments for migraine-The monoclonal antibodies and gepants. Prog Brain Res. 2020; 255: 143-170. https://doi.org/10.1016/bs.pbr.2020.06.019 |
| [39] | Shibata Y, Sato H, Sato A, Harada Y. Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan. Neurol Int. 2024; 16: 643-652. https://doi.org/10.3390/neurolint16030048 |
| [40] | Burch R. Preventive Migraine Treatment. Continuum (Minneap Minn). 2021; 27: 613-632. https://doi.org/10.1212/CON.0000000000000957 |
| [41] | Rhyne C, Cohen JM, Seminerio MJ, Carr K, Krasenbaum LJ. Burden of migraine with acute medication overuse or psychiatric comorbidities and treatment with CGRP pathway-targeted monoclonal antibodies: A review. Medicine. 2023; 102: e33874. https://doi.org/10.1097/MD.0000000000033874 |
| [42] | Liu Y, Zhou MD, Zheng YQ, Sun MS, Wang ZW, Cai DJ, et al. Acupuncture relieves pain by inhibiting expression of Cx43 in astrocytes and release of interfe-ron-γ in neurons of trigeminal spinal nucleus in rats with migraine. Zhen Ci Yan Jiu. 2023; 48: 118-224. https://doi.org/10.13702/j.1000-0607.20220967 |
| [43] | Tang X, Chen H, Zhao M, Yang W, Shuang R, Xu S. α7nAChR-mediated astrocytic activation: A novel mechanism of Xiongzhi Dilong decoction in ameliorating chronic migraine. J Ethnopharmacol. 2024; 334: 118509. https://doi.org/10.1016/j.jep.2024.118509 |
| [44] | Daverey A, Agrawal SK. Curcumin alleviates oxidative stress and mitochondrial dysfunction in astrocytes. Neuroscience. 2016; 333: 92-103. https://doi.org/10.1016/j.neuroscience.2016.07.012 |
| [45] | Carta S, Chiodega V, Tiberi R, Pasquali A, Ferrari S, Bozzetti S, et al. GFAP as a marker of astrocytic damage correlated with medication overuse in migraine. Immunol Res. 2025; 73: 119. https://doi.org/10.1007/s12026-025-09674-x |
| [46] | Gozalov E, Karlsson WK, Christensen RH, Al-Khazali HM, Hansen MB, Olsen DA, et al. Serum GFAP and NfL levels in migraine: A registry for migraine (REFORM) study. Cephalalgia. 2025; 45: 3331024251338178. https://doi.org/10.1177/03331024251338178 |
| [47] | Chiotis K, Johansson C, Rodriguez-Vieitez E, Ashton NJ, Blennow K, Zetterberg H, et al. Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer's disease with multi-modal PET and plasma GFAP. Mol Neurodegener. 2023; 18: 60. https://doi.org/10.1186/s13024-023-00647-y |
| [48] | Fatemi SH, Folsom TD, Reutiman TJ, Pandian T, Braun NN, Haug K. Chronic psychotropic drug treatment causes differential expression of connexin 43 and GFAP in frontal cortex of rats. Schizophr Res. 2008; 104: 127-134. https://doi.org/10.1016/j.schres.2008.05.016 |
| [49] | Chekhonin VP, Baklaushev VP, Yusubalieva GM, Belorusova AE, Gulyaev MV, Tsitrin EB, et al. Targeted delivery of liposomal nanocontainers to the peritumoral zone of glioma by means of monoclonal antibodies against GFAP and the extracellular loop of Cx43. Nanomedicine. 2012; 8: 63-70. https://doi.org/10.1016/j.nano.2011.05.011 |
| [50] | Fried NT, Maxwell CR, Elliott MB, Oshinsky ML. Region-specific disruption of the blood-brain barrier following repeated inflammatory dural stimulation in a rat model of chronic trigeminal allodynia. Cephalalgia. 2018; 38: 674-689. https://doi.org/10.1177/0333102417703764 |
| [51] | Turcato F, Almeida C, Mota C, Kusuda R, Carvalho A, Nascimento GC, et al. Dynamic expression of glial fibrillary acidic protein and ionized calcium binding adaptor molecule 1 in the mouse spinal cord dorsal horn under pathological pain states. Neurol Res. 2019; 41: 633-643. https://doi.org/10.1080/01616412.2019.1603804 |
Join the Editorial Board
We invite active, qualified and high profile scientists and researchers to join as Editorial Board Members.
Join UsBecome a Reviewer
Scholars with a strong interest in reviewing are invited to join the reviewer panel to ensure the quality of the research to be published.
Join Us